Approved for use through 10/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/644,579-Conf. #5200 Application Number INFORMATION DISCLOSURE August 20, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Connie Sanchez 1617 Art Unit (Use as many sheets as necessary) Y. S. Chong Examiner Name 05432/100M919-US1 of Sheet 1 Attorney Docket Number

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	1	US-6,150,376	11-21-2000	Kozikowski et al.					
	2	US-5,776,969	07-07-1998	James					
	3	US-5,747,494	05-05-1998	Medjad et al.					
	4	US-20040029958	02-12-2004	Sanchez et al.					
	5	US-6,469,064	10-22-2002	Druzgala					
	6	US-4,079,135	03-14-1978	Maisey et al.					
1		\							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear					
	7	EP-0814084-A1	12-29-1997	Eli Lilly Co.						
	8	WO-9913877	03-25-1999	Astra AB et al.						
	9	WO-0112175	02-22-2001	Vela Pharmaceuticals Inc.						

Examiner		ate	
Signature	Co	onsidered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English locations. Targetation is attempted. possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449/PTO	•••••		Complete if Known		
g Gustinus				Application Number	10/644,579-Conf. #5200	
INF	ORMATIO	N DI	SCLOSURE	Filing Date	August 20, 2003	
STA	TEMENT	BY A	APPLICANT	First Named Inventor	Connie Sanchez	
				Art Unit	1617	
(Use as many sheets as necessary)				Examiner Name	Y. S. Chong	
Sheet	2	of	4	Attorney Docket Number	05432/100M919-US1	

wwwinnin		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	,,,,,,,,,
Examiner Initials	Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	10	Notice of Opposition to EP Patent No. 1 200 081 filed by EGIS GYOGYSZERGYAR NYRT. (June 14, 2007)	
	11	Notice of Opposition to EP Patent No. 1 200 081 filed by GENERICS (UK) LIMITED. (June 19, 2007)	
	12	Notice of Opposition to EP Patent No. 1 200 081 filed by HEXAL PHARMA AG. (June 20, 2007)	
	13	Notice of Opposition to EP Patent No. 1 200 081 filed by Pliva Hrvatska d.i.i. (June 21, 2007)	
	14	Notice of Opposition to EP Patent No. 1 200 081 filed by Richter Gedeon R.T. (June 20, 2007)	
	15	Notice of Opposition to EP Patent No. 1 200 081 filed by TEVA PHARMACEUTICAL INDUSTRIES LTD. (June 20, 2007)	
	16	NZ Examination Report for NZ App. No. 569150 (June 24, 2008)	
	17	E.J. ARIENS "Chirality in Bioactive Agents and its Pitfails." TIPS, May 1986:200-205.	
	18	P. BAUMANN, "Care of depression in the elderly: comparative pharmacokinetics of SSRIs," International Clinical Psychopharmacology 1998. Vol. 13 (suppl 5) S35-S43.	
	19	R.J. BOERNER, et al. "The Importance of new Antidepressants in the Treatment of Anxiety/Depressive Disorders. Pharmacopsychiat. 32 (1999): 119-126.	
	20	BONDOLFI, "Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation," Psychopharmacology (1996) 128:421-425.	
	21	O. BRAWMAN-MINTZER, "Psychiatric Comorbidity in Patients with Generalized Anxiety Disorder," Am J Psychiatry 150:8, August 1993, pp 1216 - 1218.	
	22	K. M. CONNOR, "Generalized Anxiety Disorder: Neurobiological and Pharmacotherapeutic Perspectives," Biol Psychiatry 1998; 44:1286-1294.	-
	23	CUTLER, "A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of lpsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial," Journal of Clinical Psychopharmacology, Vo. 13, No. 6, (1993), pp. 429-437.	
	24	Larry CULPEPPER, M.D., "Escitalopram: A New SSRI for the Treatment of Depression in Primary Care," Primary Care Companion J. Clin Psychiatry 2002:4(6) pp. 209 - 214.	
	25	N. P. EMMANUEL, "Sertraline in Generalized Anxiety Disorder, A Case Series," Psychopharmacology Bulletin p. 518	-
	26	Fachinformation, Cipralex® (Escitalopram) (10 mg/20 mg) (Product Description)	
	27	Fachinformation, Cipramil® (Citalopram) (20 mg/40 mg) (Product Description)	
	28	FDA's Policy Statement for the Development of New Steroisomeric Drugs, FDA website, <a href="http://www.fda.gov/cder/guidance/stereo.htm">http://www.fda.gov/cder/guidance/stereo.htm</a> , printed September 5, 2007	
	29	"Forest Aerobid Market Share is Stable at 10%-10.5%, Firm Reports. (September 28, 1998) Vol. 60, No. 39, p. 19.	

			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Framiner I		Date	
		0	
1Signature 1	rata na mata na arata a a mananda a mada da	{ Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/644,579-Conf. #5200	
11	NFORMATION	l DI	SCLOSURE	Filing Date	August 20, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Connie Sanchez	
				Art Unit	1617	
(Use as many sheets as necessary)		Examiner Name	Y. S. Chong			
Sheet	3	of	4	Attorney Docket Number	05432/100M919-US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	30	Shinji HASHIMOTO, Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats, European Journal of Pharmcology 378 (1999) 23-30.	
	31	Shinji HASHIMOTO, Effects of the Co-administration of 5-HT1a Receptor Antagonists with an SSRI in Conditioned Fear Stress-Induced Freezing Behavior, Pharmacology Biochemistry and Behavior, Vol. 58, No. 2, pp. 471-475, 1997.	
	32	Shinji HASHIMOTO, Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats, Psychopharmacology (1996) 123: pp. 182-186.	
	33	S. HOGG, The antidepressant effects of citalopram are mediated by the S-(+) and not the R(-) entantiomer, European Neuropsychopharmacology, Vol. 9, Supplement 5, 1999, p. S213.	
	34	A.J. HUTT, Drug Chirality and its Clinical Significance," Drugs 1996: 52, Suppl. 5, pp. 1-12.	
	35	Takeshi INOUE, Serotonergic Activation Reduces Defensive Freezing in the Conditioned Fear Paradigm, Pharmacology Biochemistry and Behavior, Vol. 53, No. 4, pp. 825-831, 1996.	
	36	M. KOSEL, Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography, Journal of Chromatography B, 719 (1998) pp. 234-238.	
	37	Y.W. Francis LAM, Pharm. D. Stereoselectivity: An Issue of Significant Importance in Clinical Pharmacology, Pharmacotheraphy, Vol. 8, No. 3, 1988, pp 147-157.	
	38	G. LAUX, Psychoopharmacological Treatment of Anxiety Disorders, Therapeutische Umschau, Vol. 54, No. 10, 1997, pp. 595-599.	
	39	LEPOLA et al., Citalopram in Anxiety Disorder of Childhood and Adolescence, Eur. Child. Adol. Psych., 1994 3(4):277-279.	
	40	LEPOLA et al., The effect of citalopram in panic disorder and agoraphobia, Nord. J. Psych., 1994, 48:13-17.	
	41	J.P. LHUILLIER, Maprotiline Drops: Pilot Study in Anxiety Adaptative Disorders, Psychiatry Today: Accomplishments and Promises, International Congress Series, Elsevier Science Publishers B.V., 1989.	
	42	Lundbeck Annual Report 1999 (C. G. GOTTFRIES, "Citalopram benefits society," p. 26)	
	43	Lundbeck Annual Report 1998 (Development Projects, p. 68)	
	44	R. B. LYDIARD, Recent Developments in the Psychopharmacology of Anxiety Disorders, Journal of Consulting and Clinical Psychology 1996 Vol. 64, No. 4, pp 660-668.	
	45	W. MAIER, The Epidemiology of comorbidity between depression, anxiety disorders and somatic diseases, International Clinical Psychopharmacological, May 1999: 14 Suppl 2: S1-6.	
	46	Merck Manual of Diagnostics, Home Edition, 1997, pp. 438-447	
	47	S. NOBLE, Citalopram: A Review of its Pharmacology, Clinical Efficacy, and Tolerability in the Treatment of Depression, CNS Drugs 1997 Nov: 8 (5): 410-431	
	48	G. PARKER, Early onset depression: the relevance of anxiety, Soc Psychiatry Psychiatr Epidemiol (1997) 32: 30-37.	
	49	Psychopharmaka Rote Liste 1998, Cipramil® (Citalopram HBr) p. 127.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

05432/100M919-US1

Complete if Known Substitute for form 1449/PTO Application Number 10/644,579-Conf. #5200 **INFORMATION DISCLOSURE** Filing Date August 20, 2003 Connie Sanchez STATEMENT BY APPLICANT First Named Inventor Art Unit 1617 (Use as many sheets as necessary) Y. S. Chong Examiner Name

Attorney Docket Number

4

4

of

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	50	RAGNESKOG et al., Long-Term Treatment of Elderly Individuals With Emotional Disturbances: An Open Study With Citalopram, Int. Psychoger., 1996 8(4):659-668.	
	51	Karl RICHELS, M.D., Antidepressants for the Treatment of Generalized Anxiety Disorder, Arch Gen Psychiatry Vol. 50, Nov. 1993, pp 884-895.	
	52	P. ROCCA, Paroxetine efficacy in the treatment of generalized anxiety disorder, Acta Psychiatr Scand 1997: 95: 444-450.	
	53	B. ROCHAT, Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid Chromatography, Therapeutic Drug Monitoring, 17:273-279 (1993).	
	54	SANCHEZ et al., R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety, Pharm. Biol. Behav., 2003 75:903-907.	
	55	Jagdev SIDHU, Steady-State Pharmacokinetics of the Enantiomers of Citalopram and Its Metabolites in Humans, Chirality 9:686-692 (1997).	
	56	T. SILVERSTONE, Drugs in the treatment of Anxiety, New Zealand Journal of Psychology Vol. 25, No. 1, June 1996.	
	57	L. A. SORBERA, Escitalopram Oxalate, Drugs of the Future 2001 26(2): 115-120.	
	58	E.H. UHLENHUTH, International Study of Expert Judgment on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: VI. Trends in Recommendations for the Pharmacotherapy of Anxiety disorders, 1992-1997, Depression and Anxiety 9:107-119 (1999).	
	59	WADE et al., The effect of citalopram in panic disorder, Br. J. Psychiatry, 1997, 170:549-553	F
			<u>_</u>
			L
			H
	•		Ľ

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.